Buscar

Mostrando ítems 1-10 de 31

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

2015- Gómez-Reino Carnota, Juan Jesús

Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexa

2015- Gómez-Reino Carnota, Juan Jesús

Predictors of Response to TNF Antagonists

2015- Gómez-Reino Carnota, Juan Jesús; Maneiro Fernández, José Ramón; Salgado Pérez, Eva

High Sodium Intake Is Associated With Self-Reported Rheumatoid Arthritis: A Cross Sectional and Case Control Analysis Within the SUN Cohort

2015- Salgado Pérez, Eva; Bes-Rastrollo, M.; de Irala, J.; Carmona Ortells, Loreto; Gómez-Reino Carnota, Juan Jesús

Long-Term (104 Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials

2015- Gómez-Reino Carnota, Juan Jesús

Eficacia y seguridad de golimumab anadido a farmacos antirreumaticos modificadores de la enfermedad en artritis reumatoide. Resultados del estudio GO-MORE en Espana

2015- Gómez-Reino Carnota, Juan Jesús

Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study

2015- Montes Martínez, Ariana María; Pérez Pampín, Eva; Navarro-Sarabia, F.; Moreira, V.; de la Serna, A. R.; [et al.]

Replication of GWAs of response to TNF inhibitors in patients with rheumatoid arthritis

2015- Gómez-Reino Carnota, Juan Jesús; González Martínez-Pedrayo, Antonio; Montes Martínez, Ariana María; Pérez Pampín, Eva; Ferreiro Iglesias, Aida

LONG-TERM (104-WEEK) EFFICACY AND SAFETY PROFILE OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A PHASE III, RANDOMIZED, CONTROLLED TRIAL AND OPEN-LABEL EXTENSION (PALACE 1)

2015- Gómez-Reino Carnota, Juan Jesús

Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)

2015- Gómez-Reino Carnota, Juan Jesús

1
2
3
4